A recent article recently published in the Journal of the AHA demonstrates how type diabetes can alter heart structure, leading to poor quality of life and death among patients with heart failure. In the study’s conclusions the authors explained: “In HFpEF and HFrEF, type 2 diabetes mellitus is associated with smaller left ventricular volumes, higher mitral E/e′ ratio, poorer quality of life, and worse outcomes.”
AHA Science Advisory Releases Review on Prescription Omega-3 Fatty Acid Medication
According to a recent science advisory released by the AHA, prescription omega-3 fatty acid medication reduces triglyceride levels by 20-30% among the majority of people who require treatment for high triglyceride levels. The author’s of the advisory noted: “We concluded that treatment with 4 grams daily of any of the available prescription choices is effective and can be used safely in conjunction with statin medicines that lower cholesterol.”
Study Finds Intensive Glucose-Therapy Can Lead to Severe Hypoglycemia
Recent research published in the Mayo Clinic Proceedings Journal demonstrate that intensive glucose-lowering therapy, especially among “vulnerable clinically complex adults” may lead to severe hypoglycemia. The study found that over a 2-year period, an estimated 9,578 hospitalizations and ED visits for hypoglycemia could be attributed to intensive diabetes treatment.
FARXIGA Meets Primary Endpoint in Landmark Phase III DAPA-HF Trial
AstraZeneca recently announced positive results from the landmark Phase III DAPA-HF trial demonstrating that FARXIGA (dapagliflozin) met the primary composite endpoint with a “statistically-significant and clinically meaningful reduction of cardiovascular death or the worsening of heart failure” compared to placebo. The trial was completed with patients with reduced ejection fractions on standard of care treatment, including those with and without type 2 diabetes--the first trial of its kind.
Meet Our Chairpersons
As the incoming co-president elect of the American Diabetes Association, former president of the American Heart Association, a renowned medical professor, and leading endocrinologist, Dr. Robert H. Eckel, MD has long served as a prominent clinical authority in the field of cardiovascular and metabolic health. As a vocal advocate for the official development of a cardiometabolic sub-speciality, Dr. Eckel has conducted considerable research into the relationships between lipids/lipoprotein metabolism and obesity, diabetes, and cardiovascular disease.
Best Blog
Recent reports from the American College of Cardiology (ACC) and Medscape indicate cause for immediate concern as present statistics reveal a significant portion of the cardiologist population is experiencing burnout or burnout-indicative symptoms.
